Research map: Cross-Reactive Bundibugyo Antibody Responses after Receipt of Licensed Ebola Vaccines

Back to the article

Papers in this map

  1. Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus · Chad E. Mire · 2013 · 134 citations · Cited by this paper
  2. A review of Bundibugyo virus and the 2026 outbreak: lessons for epidemic preparedness · Krutika Kuppalli · 2026 · 3 citations · Cites this paper
  3. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer · Matt D. Galsky · 2026 · 13 citations · Related
  4. Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV · Stefanie Ehrhardt · 2019 · 132 citations · Cited by this paper
  5. Congolese hospital staff cohort admitted with infectious symptoms in the setting of the Bundibugyo virus outbreak, April and May 2026, Bunia, DR Congo · Patrick Larochelle · 2026 · 2 citations · Cites this paper
  6. Health Care–Associated Infections in U.S. Hospitals, 2023 versus 2015 · 2026 · Related
  7. Single Immunization With a Monovalent Vesicular Stomatitis Virus–Based Vaccine Protects Nonhuman Primates Against Heterologous Challenge With Bundibugyo ebolavirus · Darryl Falzarano · 2011 · 86 citations · Cited by this paper
  8. Cross-reactive Bundibugyo antibody responses in Guinean survivors of Ebola virus and recipients of rVSVΔG-ZEBOV-GP (Ervebo) in an outbreak setting · Grace Hood · 2026 · 1 citation · Cites this paper
  9. Phase 3 Trial of Weekly Oral Islatravir–Lenacapavir for HIV-1 Treatment · 2026 · Related
  10. Randomized Trial of Vaccines for Zaire Ebola Virus Disease · PREVAC Study Team · 2022 · 85 citations · Cited by this paper
  11. Vaccine preparedness for Bundibugyo virus and lessons learned · Michel Pletschette · 2026 · Cites this paper
  12. Mineralocorticoid Receptor Antagonism — FINDing Another Benefit · 2026 · Related
  13. Ebola virus vaccination elicits Ebola virus–specific immune responses without substantial cross-reactivity to other filoviruses · Thembi Mdluli · 2025 · 20 citations · Cited by this paper
  14. Preferential Ebola virus glycoprotein recognition 16–17 years after Bundibugyo virus infection · Jennifer Serwanga · 2026 · Cites this paper
  15. Time to Stop? Rethinking the Duration of Maintenance Treatment in Multiple Myeloma · 2026 · Related
  16. Aligning Licensure and Recommended Use to Expedite Vaccine Access in Response to the Ongoing Bundibugyo Ebolavirus Epidemic in Central Africa · George L. O’Hara · 2026 · Cites this paper
  17. Transdermal Estradiol Patches in Prostate Cancer · 2026 · Related
  18. Early Action Review of Detection, Notification, and Response Timeliness during Cross-Border Bundibugyo Virus Disease Outbreak, Uganda, 2026 · Joshua Kayiwa · 2026 · Cites this paper
  19. Left Ventricular Unloading in High-Risk PCI · 2026 · Related
  20. Ring and community vaccination for Bundibugyo virus outbreak response: a stochastic network modelling study · Jason Randolph Andrews · 2026 · Cites this paper
  21. Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma · 2026 · Related
  22. rVSVΔG-ZEBOV-GP vaccine-induced seroreactivity to Bundibugyo virus: a cross-protection dilemma · Abhishek N. Prasad · 2026 · Cites this paper
  23. Evidence for cross-reactivity and protection against Bundibugyo virus disease after heterologous vaccination: a systematic review and meta-analysis · Eva Stadler · 2026 · Cites this paper
  24. One Health preparedness for Ebola disease caused by Bundibugyo virus: lessons from the 2026 outbreak centred in the Democratic Republic of the Congo · Yuxuan Shao · 2026 · Cites this paper

Source: OpenAlex (CC0)